Empowered Patient Podcast
Novel Anti-Inflammatory Therapeutic Agent Showing Promise for Ulcerative Colitis with Dr. Hartmut Ehrlich Abivax
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:19:12
- More information
Informações:
Synopsis
Dr. Hartmut Ehrlich, CEO, Abivax gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results. Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax #inflammation #IBD #rheum Abivax.com Download the transcript here
